L-Fucose
CAS 2438-80-4
L-Fucose (CAS 2438-80-4) is a Phase 3 pharmaceutical compound with 2 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 3746.6666666666665 nM | 6 | - |
| - | Kd | 2950 nM | 2 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is L-Fucose used for in pharmaceutical contexts?
L-Fucose (CAS 2438-80-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for L-Fucose?
No adverse-event association or SIDER side-effect rows are rendered for L-Fucose in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is L-Fucose also used in cosmetics?
No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for L-Fucose.
What clinical phase is L-Fucose in?
L-Fucose is rendered with ChEMBL max phase 3.